Boehringer Ingelheim and Brainomix have entered into a strategic partnership for a collaborative programme to improve the identification and access to treatment for people living with fibrosing lung disease in the US.
The project will evaluate the real-world impact of Brainomix’s 360 e-Lung imaging software for patients with progressive pulmonary fibrosis (PF).
Affecting up to 20 out of every 100,000 people worldwide, including 100,000 people in the US, according to the National Institutes of Health, PF is a progressive, chronic lung condition that leads to difficulty breathing and shortness of breath.
For the best outcomes for patients, early initiation of treatment can help prevent or delay progression. However, identifying patients eligible for treatment based on imaging can be challenging.
The project will focus on the use of artificial intelligence imaging analysis using Brainomix’s software on routine CT scans to accelerate diagnosis and improve access to treatment by deploying it to leading US pulmonology centres and their networks of referring sites.
The data generated will validate the value of e-Lung as well as its potential to optimise pathways of care and improve outcomes for people living with the condition through digital technology.
The e-Lung software received clearance from the US Food and Drug Administration in May 2024 and Brainomix recently announced a new series of studies to highlight its prognostic value in patients with fibrotic lung disease.
Ioannis Sapountzis, head of global therapeutic areas, Boehringer Ingelheim, said: “We believe that Brainomix 360 e-Lung has the potential to revolutionise the diagnostic landscape and thereby enable earlier treatment decisions…, ultimately improving patient outcomes and quality of life of those affected.”
Dr Michalis Papadakis, chief executive officer and co-founder, Brainomix said: “This [partnership] will enable… us to leverage our… experience and expertise connecting stroke networks to develop a similar network model of care for patients with fibrosing lung disease.”
In January, Brainomix’s e-Stroke was recommended by the National Institute for Health and Care Research (NICE) for use in the NHS for stroke diagnosis, while, prior to this, Boehringer Ingelheim’s Ofev (nintedanib) was recommended by NICE for the treatment of idiopathic pulmonary fibrosis in adults with a forced vital capacity above 80% predicted in 2022.